Yarrow Bioscience, Inc. (YARW): Long-Term Debt
$0
As of 2025-12-31
$0
As of 2026-06-30
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $0 | n/a | 2026-02-27, Balance as of period end |
| 2024-12-31 | $0 | n/a | 2025-03-06, Balance as of period end |
| 2023-12-31 | $0 | n/a | 2024-03-01, Balance as of period end |
| 2022-12-31 | $0 | n/a | 2023-03-14, Balance as of period end |
| 2021-12-31 | $0 | n/a | 2022-03-17, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | $0 | n/a |
| BioXcel Therapeutics, Inc. (BTAIQ) | 2025-12-31 | $109.59M | +6.9% |
| Scienture Holdings, Inc. (SCNX) | 2024-12-31 | $2.90M | n/a |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $150.0K | 0.0% |
| China SXT Pharmaceuticals, Inc. (SXTC) | 2025-03-31 | $807.2K | +27.8% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $60.04M | -4.2% |
| Clene Inc. (CLNN) | 2025-12-31 | $17.79M | n/a |
| Rani Therapeutics Holdings, Inc. (RANI) | 2024-12-31 | $25.00M | -16.7% |
| Bio Essence Corp (BIOE) | 2025-12-31 | $57.5K | +1.8% |
Compare YARW, BTAIQ, SCNX, SXTP side by side · Screen every company in Pharmaceutical Preparations ↗